| 000 | 00891 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250514072455.0 | ||
| 264 | 0 | _c20030916 | |
| 008 | 200309s 0 0 eng d | ||
| 022 | _a1462-2416 | ||
| 024 | 7 |
_a10.1517/phgs.4.4.443.22749 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAttar, Mayssa | |
| 245 | 0 | 0 |
_aPharmacogenomic considerations in drug delivery. _h[electronic resource] |
| 260 |
_bPharmacogenomics _cJul 2003 |
||
| 300 |
_a443-61 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDrug Carriers _xmetabolism |
| 650 | 0 | 4 |
_aDrug Delivery Systems _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPharmacogenetics _xmethods |
| 700 | 1 | _aLee, Vincent H L | |
| 773 | 0 |
_tPharmacogenomics _gvol. 4 _gno. 4 _gp. 443-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/phgs.4.4.443.22749 _zAvailable from publisher's website |
| 999 |
_c12614078 _d12614078 |
||